Literature DB >> 32348108

Hydrocarbon-Stitched Peptide Agonists of Glucagon-Like Peptide-1 Receptor.

Gregory H Bird1,2, Accalia Fu3,4, Silvia Escudero1,2, Marina Godes1,2, Kwadwo Opoku-Nsiah1,2, Thomas E Wales5, Michael D Cameron6, John R Engen5, Nika N Danial3,7,8, Loren D Walensky1,2,9.   

Abstract

Glucagon-like peptide 1 (GLP-1) is a natural peptide agonist of the GLP-1 receptor (GLP-1R) found on pancreatic β-cells. Engagement of the receptor stimulates insulin release in a glucose-dependent fashion and increases β-cell mass, two ideal features for pharmacologic management of type 2 diabetes. Thus, intensive efforts have focused on developing GLP-1-based peptide agonists of GLP-1R for therapeutic application. A primary challenge has been the naturally short half-life of GLP-1 due to its rapid proteolytic degradation in vivo. Whereas mutagenesis and lipidation strategies have yielded clinical agents, we developed an alternative approach to preserving the structure and function of GLP-1 by all-hydrocarbon i, i + 7 stitching. This particular "stitch" is especially well-suited for reinforcing and protecting the structural fidelity of GLP-1. Lead constructs demonstrate striking proteolytic stability and potent biological activity in vivo. Thus, we report a facile approach to generating alternative GLP-1R agonists for glycemic control.

Entities:  

Mesh:

Substances:

Year:  2020        PMID: 32348108      PMCID: PMC7366314          DOI: 10.1021/acschembio.0c00308

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  46 in total

1.  Reactivation of the p53 tumor suppressor pathway by a stapled p53 peptide.

Authors:  Federico Bernal; Andrew F Tyler; Stanley J Korsmeyer; Loren D Walensky; Gregory L Verdine
Journal:  J Am Chem Soc       Date:  2007-02-07       Impact factor: 15.419

2.  A Helix-Stabilizing Linker Improves Subcutaneous Bioavailability of a Helical Peptide Independent of Linker Lipophilicity.

Authors:  Liang Zhang; Tejas Navaratna; Greg M Thurber
Journal:  Bioconjug Chem       Date:  2016-06-29       Impact factor: 4.774

3.  Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration.

Authors:  L B Knudsen; P F Nielsen; P O Huusfeldt; N L Johansen; K Madsen; F Z Pedersen; H Thøgersen; M Wilken; H Agersø
Journal:  J Med Chem       Date:  2000-05-04       Impact factor: 7.446

4.  A phospho-BAD BH3 helix activates glucokinase by a mechanism distinct from that of allosteric activators.

Authors:  Benjamin Szlyk; Craig R Braun; Sanda Ljubicic; Elaura Patton; Gregory H Bird; Mayowa A Osundiji; Franz M Matschinsky; Loren D Walensky; Nika N Danial
Journal:  Nat Struct Mol Biol       Date:  2013-12-08       Impact factor: 15.369

5.  Dual-purpose linker for alpha helix stabilization and imaging agent conjugation to glucagon-like peptide-1 receptor ligands.

Authors:  Liang Zhang; Tejas Navaratna; Jianshan Liao; Greg M Thurber
Journal:  Bioconjug Chem       Date:  2015-01-28       Impact factor: 4.774

6.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes.

Authors:  Ralph A DeFronzo; Robert E Ratner; Jenny Han; Dennis D Kim; Mark S Fineman; Alain D Baron
Journal:  Diabetes Care       Date:  2005-05       Impact factor: 19.112

7.  Hydrocarbon double-stapling remedies the proteolytic instability of a lengthy peptide therapeutic.

Authors:  Gregory H Bird; Navid Madani; Alisa F Perry; Amy M Princiotto; Jeffrey G Supko; Xiaoying He; Evripidis Gavathiotis; Joseph G Sodroski; Loren D Walensky
Journal:  Proc Natl Acad Sci U S A       Date:  2010-07-21       Impact factor: 11.205

8.  Mucosal delivery of a double-stapled RSV peptide prevents nasopulmonary infection.

Authors:  Gregory H Bird; Sandhya Boyapalle; Terianne Wong; Kwadwo Opoku-Nsiah; Raminder Bedi; W Christian Crannell; Alisa F Perry; Huy Nguyen; Viviana Sampayo; Ankita Devareddy; Subhra Mohapatra; Shyam S Mohapatra; Loren D Walensky
Journal:  J Clin Invest       Date:  2014-04-17       Impact factor: 14.808

9.  Efficacy and Safety of Once-Weekly Semaglutide Versus Exenatide ER in Subjects With Type 2 Diabetes (SUSTAIN 3): A 56-Week, Open-Label, Randomized Clinical Trial.

Authors:  Andrew J Ahmann; Matthew Capehorn; Guillaume Charpentier; Francesco Dotta; Elena Henkel; Ildiko Lingvay; Anders G Holst; Miriam P Annett; Vanita R Aroda
Journal:  Diabetes Care       Date:  2017-12-15       Impact factor: 19.112

10.  Crystal structure of glucagon-like peptide-1 in complex with the extracellular domain of the glucagon-like peptide-1 receptor.

Authors:  Christina Rye Underwood; Patrick Garibay; Lotte Bjerre Knudsen; Sven Hastrup; Günther H Peters; Rainer Rudolph; Steffen Reedtz-Runge
Journal:  J Biol Chem       Date:  2009-10-27       Impact factor: 5.157

View more
  2 in total

1.  Significance of serum glucagon-like peptide-1 and matrix Gla protein levels in patients with diabetes and osteoporosis.

Authors:  Fei-Fei Xie; Yu-Fang Zhang; Yan-Fang Hu; Yun-Yun Xie; Xiao-Ying Wang; Shu-Zhen Wang; Bao-Qiang Xie
Journal:  World J Clin Cases       Date:  2022-02-16       Impact factor: 1.337

2.  Structural basis for defective membrane targeting of mutant enzyme in human VLCAD deficiency.

Authors:  Michelle S Prew; Christina M Camara; Thomas Botzanowski; Jamie A Moroco; Noah B Bloch; Hannah R Levy; Hyuk-Soo Seo; Sirano Dhe-Paganon; Gregory H Bird; Henry D Herce; Micah A Gygi; Silvia Escudero; Thomas E Wales; John R Engen; Loren D Walensky
Journal:  Nat Commun       Date:  2022-06-27       Impact factor: 17.694

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.